Source: New York Post
WASHINGTON — The Trump administration on Wednesday acted to ease access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. Food and Drug Administration scientific staffers had little input on the decision and opposed the changes, according to six people familiar with its development.
Aller á la Source
Nouvelles connexes
